Professor Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMed Sci, is Foundation Professor at St George’s University of London and Principal of the ICVI. He graduated at UCL/UCH in 1974 and was a flying doctor in Mount Isa in Australia before training in Medicine in Brisbane and Oncology in Sydney.
He did an MD on retrovirus with Professor R Weiss, FRS, at the ICR, where he published a seminal paper on HIV, its receptors and pathogenesis.
He has been focussing on tumour immunology since 1991 and developed the Thalidomide programme with Celgene, resulting in Lenalidomide, for which he received the Joshua Lederberg Prize.
After trialling over a dozen different cancer vaccines he focussed on IMM-101 combinations as the most effective for future development